Chronic Obstructive Pulmonary Disease | DecisionBase | US/EU | 2014

Amid the Emergence of a Novel Class of Dual Bronchodilators, What Are the Key Areas of Opportunity for Differentiation According to Pulmonologists and Payers?

Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and polypharmacy is commonplace as patients’ COPD worsens. Substantial opportunity exists for a disease-modifying therapy, but development of new COPD therapies has focused instead on therapies that combine two bronchodilators into one inhaler. As the COPD marketplace becomes increasingly crowded, emerging therapies will need to be clearly differentiated from competitors to garner substantial uptake.

Login to access report

launch Related Market Assessment Reports